Acute myeloïde leukemie (AML)
HOVON 150: A phase 3, multicenter, double-blind, randomized, placebo-controlled study of ivosidenib or enasidenib in combination with induction therapy and consolidation therapy followed by maintenance therapy in patients with newly diagnosed acute myeloid leukemia or myelodysplastic syndrome with excess blasts-2, with an IDH1 or IDH2 mutation, respectively, eligible for intensive chemotherapy
HOVON 156: A phase 3, multicenter, open-label, randomized study of gilteritinib versus midostaurin in combination with induction and consolidaton therapy followed by one-year maintenance in patients with newly diagnosed acute myeloid leukemia (AML) or myelodysplastic syndromes with excess blasts-2 (MDS-EB2) with FLT3 mutations eligible for intensive chemotherapy
Chronische myeloïde leukemie (CML)
HOVON 142: Sustained treatment-free remission in BCR-ABL+ chronic myeloid leukemia: a prospective study comparing nilotinib versus imatinib with switch to nilotinib in absence of optimal response
Myelodysplastisch syndroom (MDS)
EU-MDS: A prospective, multicentre European registry for newly diagnosed patients with myelodysplastic syndromes (MDS), including acute myeloid leukaemia with 20-30 percent marrow blasts (former RAEB-t), and chronic myelomonocytic leukaemia (CMML)
COMMANDS: A phase 3, open-label, randomized study to compare the efficacy and safety of luspatercept (ACE-536) versus epoetin alfa for the treatment of anemia due to IPSS-R very low, low or intermediate risk myelodysplastic syndromes (MDS) in ESA naïve subjects who require red blood cell transfusions
IMerge 2: A study to evaluate imetelstat (GRN163L) in transfusion-dependent subjects with IPSS low or intermediate-1 risk myelodysplastic syndrome (MDS) that is relapsed/refractory to erythropoiesis-stimulating agent (ESA) treatment
Myeloproliferatieve neoplasieën (MPN)
HOVON 134: A phase II trial in patients with myelofibrosis (primary, post-ET or post-PV-MF) treated with the selective JAK2 inhibitor pacritinib before reduced-intensity conditioning allogeneic stem cell transplantation
FREEDOM 2: A phase III, multi center, open-lable, randomized study to evaluate the efficacy and safety of fedratinib compared to best available therapy in subjects with DIPSS-intermediate or high-risk primary myelofibrosis, post-polycytemia vera myelofibrosis, or post-essential thrombocythemia myelofibrosis and previously treated with ruxolitinib
Hodgkin lymfoom (HL)
COBRA: Very early FDG-PET-response adapted targeted therapy for advanced Hodgkin lymphoma: a single-arm phase II study
Non Hodgkin lymfomen (NHL)
HOVON 127: Phase III study comparing R-CODOX-M/R-IVAC versus dose-adjusted EPOCH-R (DA-EPOCH-R) for patients with newly diagnosed high risk Burkitt lymphoma
HOVON 133 / TRIANGLE: Autologous transplantation after a rituximab/ibrutinib/ara-c containing induction in generalized mantle cell lymphoma – A randomized European MCL network trial
HOVON 136: Phase I-II study combining brentuximab vedotin with second line salvage chemotherapy (R-DHAP) in CD30 positive diffuse large B-cell lymphoma patients refractory to first line chemotherapy or in first relapse who are eligible for high dose treatment followed by autologous stem cell transplantation
HOVON 152: A phase II study evaluating the effect of DA-EPOCH-R induction followed by nivolumab consolidation in patients with newly diagnosed high grade B cell lymphoma (HGBL) with MYC and BCL2 and/or BCL6 rearrangements
Stamceltransplantatie (SCT)
PSCT19: Vaccination with PD-L1/L2-silenced minor histocompatibility antigen-loaded donor DC vaccines to boost graft-versus-tumor immunity after allogeneic stem cell transplantation (a phase I/II study)
Auto-immuun hemolytische anemie (AIHA)
DRAIHA: Data registry of autoimmune hemolytic anemia, to improve diagnostic testing for the development of personalized treatment protocols in AIHA patients
Supportive care
ORASTEM: Oral complications in patients treated with hematopoietic stem cell transplantation
AzoR-Man: PCR based detection of azole resistance in A. fumigatus to improve patient outcome. A prospective multicentre intervention study
AFFECT-2: Efficacy of interleukin-1 pathway inhibitor anakinra for the management of fever during neutropenia and mucositis in patients with multiple myeloma receiving an autologous hematopoietic stem cell transplantation after high-dose melphalan
CLARITY: Cardiotoxicity and other late effects after radiotherapy and immuno-chemotherapy for non-Hodgkin lymphoma
F2G: An open-label single-arm Phase IIb study of F901318 as treatment of invasive fungal infections due to Lomentospora prolificans, Scedosporium spp., Aspergillus spp., and other resistant fungi in patients lacking suitable alternative treatment options
PLATO: Farmacokinetiek van teicoplanine bij patiënten met een infectie op de Intensive Care en Hematologie afdeling
Transfusiegeneeskunde
PACER: A randomized controlled trial on prophylactic platelet transfusion prior to central venous catheter placement in patients with trombocytopenia
BITE: A nationwide epidemiological and laboratory case cohort study investigating risk factors for bleeding in hemato-oncology patients
Stolling
PRO-RBDD: Prospective data collection on patients with rare bleeding disorders
RBiN: Rare bleeding disorders in the Netherlands
HemoNED: Landelijk register van patiënten met hemofilie en aanverwante aandoeningen
CoFAB: Coagulation factor deficiencies biobank Maastricht
DAVID: DDAVP treatment combined with FVIII clotting factor concentrates in patients with mild hemophilia A
Little DAVID: Desmopressin and FVIII concentrate combination treatment in non-severe hemophilia A patients undergoing minor interventions
Obizur EU PASS: Prospective, non-interventional study to evaluate the safety and effectiveness of Obizur in real-life practice
PRIDES: Observational study on pregnancy outcome in women with inherited bleeding disorders
Hemoglobinopathie
STARRING: Sickle cell disease: targeting alloantibody formation reduction; risk factors, and genetics
Paroxysmale nachtelijke hemoglobinurie (PNH)
RPNH01: Paroxysmal nocturnal hemoglobinuria (PNH) registry
AK581: Akari long term safety coversin
DAHLIA / ABP959: A randomized, double-blind, active-controlled phase 3 study evaluating the efficacy and safety of ABP 959 compared with eculizumab in adult subjects with paroxysmal nocturnal hemoglobinuria (PNH)
Ga terug naar de algemene homepage Studieprotocollen.